SAN FRANCISCO, June 21, 2016 /PRNewswire/ -- entrotech life sciences (ELS) (www.entrotechlifesciences.com) recently announced the availability of FDA-Cleared ChloraDerm™ in a new design with a reinforced border, ideal for advanced IV catheter securement. ChloraDerm™ is the first and only transparent film dressing containing the Chlorhexidine Advantage™, a safe, colophony-and acid-free, edge-to-edge chlorhexidine matrix with effectiveness against multi-drug-resistant organisms, including MRSA for at least seven days.
The ChloraDerm platform was recently launched by entrotech life sciences, an innovative company that is taking its expertise in life-saving products from the military battlefield to the hospital bed-side. The new design integrates a soft cloth reinforced border into the ChloraDerm dressing platform providing healthcare providers with added comfort and securement feature for IV catheter sites when more robust dressing security and stability are required for the patient.
"Both the patient and healthcare provider will benefit from ChloraDerm's new securement offering," said ELS CEO Jim McGuire. "Our demonstrated ability to rapidly develop and commercialize life-saving technologies is instrumental to reducing preventable infections around the globe."
ChloraDerm™ is used to cover and secure primary dressings and protect wounds with percutaneous medical devices that could result in a central line associated bloodstream infection (CLABSI). ChloraDerm achieves >4 Log10 reduction against yeasts and gram positive and negative bacteria, including multiple drug-resistant organisms (MRSA, MRSE, VRE, MDR. Compared to common non-antimicrobial dressings, ChloraDerm™ demonstrates substantially greater effectiveness against these organisms at one, three and seven days, without adding increased cost or complexity. CLABSI's afflict nearly 100,000 people per year and can cause severe harm or death. The 2011 CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections recommend Chlorhexidine impregnated dressings be considered for Central Venous Catheter CLABSI prevention.1
about entrotech life sciences
entrotech life sciences (ELS | San Francisco, CA) pioneered a platform technology that eluded researchers for the past 20 years through the invention of a patent-pending, non-thermal process for creating polymeric materials containing active chlorhexidine, the most effective antimicrobial for reducing skin bacteria. entrotech life sciences helps healthcare professionals committed to infection prevention rethink what is possible in protection of catheter and surgical patients. ELS is affiliated with Entrogroup (est. 1999), an organization focused on inventing advanced lifesaving combat military products, smart device protectors, and environmentally-friendly, and lightweight paint appliques. Visit: www.entrotechlifesciences.com/chloraderm
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/entrotech-life-sciences-launches-chloraderm-iv-securement-portfolio-300288085.html
SOURCE entrotech life sciences